Hosted on MSN1mon
Neurocrine Biosciences director Kevin Gorman sells $413,966 in stock
Neurocrine Biosciences Inc. (NASDAQ ... According to a filing with the Securities and Exchange Commission, Director Kevin Charles Gorman sold 2,707 shares at a weighted average price of ...
Hosted on MSN27d
Neurocrine Biosciences director sells $681,913 in stock
SAN DIEGO—Kevin Charles Gorman, a director at Neurocrine Biosciences Inc. (NASDAQ:NBIX), sold a total of 5,844 shares of the company's common stock on February 13, 2025, according to a recent ...
Hosted on MSN29d
Neurocrine Biosciences director sells shares worth $269,167
Kevin Charles Gorman, a director at Neurocrine Biosciences Inc. (NASDAQ:NBIX), executed several stock transactions recently, according to a filing with the Securities and Exchange Commission.
pharmaphorum7y
Neurocrine achieves a first with tardive dyskinesia drug Ingrezza
For CEO Kevin Gorman, the approval will be a vindication of many years work: he founded the company back in 1992, and suffered numerous setbacks along the way. Now Neurocrine Bioscience ...
Hosted on MSN1mon
Neurocrine Biosciences director sells shares worth $21.8 million
Kevin Charles Gorman, a director at Neurocrine Biosciences Inc. (NASDAQ:NBIX), recently sold a significant portion of his holdings in the company. According to a recent SEC filing, Gorman sold ...
CNN4y
Neurocrine Biosciences, Inc.
Neurocrine Biosciences ... The company was founded by Kevin C. Gorman and Wylie W. Vale in January 1992 and is headquartered in San Diego, CA.